Trial Profile
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Propranolol/etodolac (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Vicus Therapeutics
- 08 Dec 2015 Planned End Date changed from 1 Nov 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 16 Jan 2015 Results were presented at the 2015 Gastrointestinal Cancers Symposium, according to a Vicus Therapeutics media release.
- 16 Jan 2015 Results published in a Vicus Therapeutics media release.